{"title":"有胃肠道症状的伊朗患者Barrett食管患病率:系统回顾和荟萃分析。","authors":"Maryam Rashidian, Fatemeh Bastan, Hedieh Soltani, Reza Ghosheni, Kiyarash Bakhshande, Mahdi Mohammaditabar, Yasin Tabatabaei Mehr, Khaled Rahmani, Mahmood Bakhtiyari, Mostafa Qorbani, Mojgan Forootan, Mahsa Mohammadi, Mohsen Rajabnia","doi":"10.1186/s12876-025-03822-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Barrett's esophagus (BE) is a premalignant columnar metaplasia of the esophagus that predisposes victims to esophageal adenocarcinoma (EAC). Depending on differences in the study population and risk factors, the prevalence of BE may vary, from 0.4 to 20% globally. The current study aimed to systematically review and analyse the prevalence of BE in in patients with gastrointestinal symptoms in Iran. Furthermore, gastrointestinal malignancies are among the most common tumours in Iran, making this study even more significant.</p><p><strong>Methods: </strong>A systematic search was carried out in PubMed, Web of Science, Scopus, and EMBASE as well as some domestic databases including SID, Magiran, IranDoc, IranMedex from inception to the end of 2023. We included all cross-sectional studies which reported the prevalence of BE and calculated pooled prevalence.</p><p><strong>Results: </strong>The results of the analysis, including 9 studies in a total of 4978 cases (213 Barret diagnoses), revealed that by the results of these studies, the prevalence of Barret's esophagus is 4.4% [I2 = 94.9% [92.2%; 96.6%]/p-value < 0.0001]. Subgroup analysis, divided by region and year, revealed significant differences between groups.</p><p><strong>Conclusions: </strong>The epidemiology of BE in Iran is not completely identified. This is the first systematic review and meta-analysis evaluating the prevalence and of BE in Iran. Due to the importance of BE in progressing to esophageal adenocarcinoma, much importance should be given to its timely diagnosis. It is strongly recommended to conduct more comprehensive studies including more patients in this field.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"217"},"PeriodicalIF":2.5000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11966864/pdf/","citationCount":"0","resultStr":"{\"title\":\"The prevalence of Barrett 's esophagus in Iranian patients with gastrointestinal symptoms: a systematic review and meta-analysis.\",\"authors\":\"Maryam Rashidian, Fatemeh Bastan, Hedieh Soltani, Reza Ghosheni, Kiyarash Bakhshande, Mahdi Mohammaditabar, Yasin Tabatabaei Mehr, Khaled Rahmani, Mahmood Bakhtiyari, Mostafa Qorbani, Mojgan Forootan, Mahsa Mohammadi, Mohsen Rajabnia\",\"doi\":\"10.1186/s12876-025-03822-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Barrett's esophagus (BE) is a premalignant columnar metaplasia of the esophagus that predisposes victims to esophageal adenocarcinoma (EAC). Depending on differences in the study population and risk factors, the prevalence of BE may vary, from 0.4 to 20% globally. The current study aimed to systematically review and analyse the prevalence of BE in in patients with gastrointestinal symptoms in Iran. Furthermore, gastrointestinal malignancies are among the most common tumours in Iran, making this study even more significant.</p><p><strong>Methods: </strong>A systematic search was carried out in PubMed, Web of Science, Scopus, and EMBASE as well as some domestic databases including SID, Magiran, IranDoc, IranMedex from inception to the end of 2023. We included all cross-sectional studies which reported the prevalence of BE and calculated pooled prevalence.</p><p><strong>Results: </strong>The results of the analysis, including 9 studies in a total of 4978 cases (213 Barret diagnoses), revealed that by the results of these studies, the prevalence of Barret's esophagus is 4.4% [I2 = 94.9% [92.2%; 96.6%]/p-value < 0.0001]. Subgroup analysis, divided by region and year, revealed significant differences between groups.</p><p><strong>Conclusions: </strong>The epidemiology of BE in Iran is not completely identified. This is the first systematic review and meta-analysis evaluating the prevalence and of BE in Iran. Due to the importance of BE in progressing to esophageal adenocarcinoma, much importance should be given to its timely diagnosis. It is strongly recommended to conduct more comprehensive studies including more patients in this field.</p>\",\"PeriodicalId\":9129,\"journal\":{\"name\":\"BMC Gastroenterology\",\"volume\":\"25 1\",\"pages\":\"217\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-04-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11966864/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Gastroenterology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12876-025-03822-1\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12876-025-03822-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:Barrett食管(BE)是一种食管癌前柱状化生,易患食管腺癌(EAC)。根据研究人群和危险因素的差异,BE的患病率可能有所不同,全球范围从0.4%到20%不等。本研究旨在系统回顾和分析伊朗胃肠道症状患者中BE的患病率。此外,胃肠道恶性肿瘤是伊朗最常见的肿瘤之一,这使得这项研究更加重要。方法:系统检索PubMed、Web of Science、Scopus、EMBASE以及SID、Magiran、IranDoc、IranMedex等国内数据库,检索时间自建库至2023年底。我们纳入了所有报告BE患病率并计算总患病率的横断面研究。结果:分析9篇研究共4978例病例(Barret诊断213例),结果显示:Barret食管患病率为4.4% [I2 = 94.9% [92.2%];结论:伊朗BE的流行病学尚未完全确定。这是第一个评估伊朗BE患病率的系统综述和荟萃分析。由于BE在进展为食管腺癌中的重要性,因此应重视其及时诊断。强烈建议在该领域开展更全面的研究,包括更多的患者。
The prevalence of Barrett 's esophagus in Iranian patients with gastrointestinal symptoms: a systematic review and meta-analysis.
Background: Barrett's esophagus (BE) is a premalignant columnar metaplasia of the esophagus that predisposes victims to esophageal adenocarcinoma (EAC). Depending on differences in the study population and risk factors, the prevalence of BE may vary, from 0.4 to 20% globally. The current study aimed to systematically review and analyse the prevalence of BE in in patients with gastrointestinal symptoms in Iran. Furthermore, gastrointestinal malignancies are among the most common tumours in Iran, making this study even more significant.
Methods: A systematic search was carried out in PubMed, Web of Science, Scopus, and EMBASE as well as some domestic databases including SID, Magiran, IranDoc, IranMedex from inception to the end of 2023. We included all cross-sectional studies which reported the prevalence of BE and calculated pooled prevalence.
Results: The results of the analysis, including 9 studies in a total of 4978 cases (213 Barret diagnoses), revealed that by the results of these studies, the prevalence of Barret's esophagus is 4.4% [I2 = 94.9% [92.2%; 96.6%]/p-value < 0.0001]. Subgroup analysis, divided by region and year, revealed significant differences between groups.
Conclusions: The epidemiology of BE in Iran is not completely identified. This is the first systematic review and meta-analysis evaluating the prevalence and of BE in Iran. Due to the importance of BE in progressing to esophageal adenocarcinoma, much importance should be given to its timely diagnosis. It is strongly recommended to conduct more comprehensive studies including more patients in this field.
期刊介绍:
BMC Gastroenterology is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of gastrointestinal and hepatobiliary disorders, as well as related molecular genetics, pathophysiology, and epidemiology.